Life Sciences
Hope May Be Misplaced in General Electric's Turnaround as Recession Risk Looms
Time could run out before Larry Culp can complete his turnaround plan at GE.
GE Stock Jolted as Key Analyst Cuts Target Price
GE stock hasn't solved its free cash flow conundrum, and might not for some time, says a key analyst.
Fluidigm Is Emerging From a Large Base Pattern, So Go Long
The stock of the maker of life sciences research technology is trading in the low teens, but a key chart indicates no price resistance until the low $20s.
Activists Aim to Eliminate Dual Role for Allergan CEO Saunders
David Tepper's Appaloosa LP renews calls for changes at the top.
DowDuPont Regains Some Footing but Still Could Retest Recent Lows
A key chart suggests further gains in the chemical giant are possible, but be aware that it could explore lower levels of October again.
Video: Jim Cramer Reacts to Biogen's Surge
Biogen shares rose 15% Friday following upbeat results from an Alzheimer's drug test.
It's Dumb to Think Legalizing Weed Is Still a Political Issue
What was once a red and blue issue has now attracted a growing set of proponents from both sides of the aisle.
Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis
Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.